Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammatory processes that result in joint swelling, inflammation, and the onset of pain. This discomfort and pathological condition exhibit a gradual rise in scale and become more intense. Even though pharmacotherapy like disease-modifying antirheumatic drugs (DMARDs) and biologics has improved, there is still a need for more focused treatments that cause less harm. This study examines how treatments for RA have changed over time, focusing on the shift from traditional medicines to new, creative ways to combine medicine with immune-engineering therapies. DMARDs are still the most common way to treat RA. On the other hand, biologics and Janus kinase inhibitors are options for people who do not react to their first medications. The development of nanomedicines and hydrogels is an exciting new area of study because they make it possible for more precise spread and less overall toxicity of the medicine. The early research suggests that these innovative approaches could greatly improve the effectiveness of therapy by delivering drugs directly to the site of inflammation while also reducing the severity of any side effects that might occur. RA care is quickly expanding beyond the traditional use of drugs to include more modern ways of managing medications and also personalized healing methods.
Ghazanfari, M. R., & Sepehrnia, S. (2024). Reviewing Advances in Rheumatoid Arthritis Treatment: From Disease-modifying Antirheumatic Drugs to Innovative Drug Delivery Systems. Immunoregulation, 6(2), 105-118. doi: 10.32598/Immunoregulation.6.2.4
MLA
Mohammad Reza Ghazanfari; Saeed Sepehrnia. "Reviewing Advances in Rheumatoid Arthritis Treatment: From Disease-modifying Antirheumatic Drugs to Innovative Drug Delivery Systems". Immunoregulation, 6, 2, 2024, 105-118. doi: 10.32598/Immunoregulation.6.2.4
HARVARD
Ghazanfari, M. R., Sepehrnia, S. (2024). 'Reviewing Advances in Rheumatoid Arthritis Treatment: From Disease-modifying Antirheumatic Drugs to Innovative Drug Delivery Systems', Immunoregulation, 6(2), pp. 105-118. doi: 10.32598/Immunoregulation.6.2.4
VANCOUVER
Ghazanfari, M. R., Sepehrnia, S. Reviewing Advances in Rheumatoid Arthritis Treatment: From Disease-modifying Antirheumatic Drugs to Innovative Drug Delivery Systems. Immunoregulation, 2024; 6(2): 105-118. doi: 10.32598/Immunoregulation.6.2.4
)
